Merck says still plans Cubist purchase, despite patent setback

By | 09/12/2014

(Reuters) – Merck & Co on Tuesday said it will proceed with its planned $8.4 billion (5.3 billion pounds) purchase of Cubist Pharmaceuticals and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist’s top-selling product.

Link to article:

Category: Business Tags:

About PentaBytes

PentaBytes is a Blog or Digital Magazine with direct link for the best selected news in real time. The last news about Technology, Economy, Business, Startups, Society, Travel, etc. Interviews and interesting articles. You can contact with us in the contact page. Thanks.

Leave a Reply

Your email address will not be published. Required fields are marked *